Therapy News and Research

RSS

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from a 36-week active extension study evaluating two doses of laquinimod, an investigational, once-daily oral immunomodulator, for the treatment of relapsing remitting multiple sclerosis.

21 Sep 2010

NIMU, NMRC sign CRADA agreement

Non-Invasive Monitoring Systems, Inc. announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center (NMRC) in Silver Springs, MD to evaluate the benefit of Exer-Rest for patients with traumatic brain injury (TBI).

21 Sep 2010

Scientists identify new pathway to control immune balance

St. Jude Children's Research Hospital scientists have identified a new pathway that helps control the immune balance through reciprocal regulation of specialized T lymphocytes, which play very different inflammatory roles.

21 Sep 2010

Talecris Biotherapeutics announces 2010 eALTA award recipients

Talecris Biotherapeutics GmbH announced yesterday the recipients of the 2010 European alpha1-antitrypsin Laurell's Training Awards (eALTA). The annual awards, sponsored by Talecris, provide two fellowships of 50,000 euros to young investigators whose research aims to enhance the understanding and treatment of alpha1-antitrypsin deficiency (AAT deficiency).

21 Sep 2010

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

Gastric cancer is a major cause of cancer deaths in the world. The outcome of large gastric tumors and those with lymph node involvement remains poor after surgical resection. The optimal adjuvant therapy after surgical resection remains to be determined.

21 Sep 2010

FG-4592 oral anemia therapy receives CTA approval from SFDA

FibroGen, Inc., today announced that its investigational oral anemia therapy, FG-4592, received Clinical Trial Application (CTA) approval from the Chinese State Food and Drug Administration (SFDA) to commence clinical development for the treatment of anemia associated with chronic kidney disease (CKD) in the People's Republic of China.

21 Sep 2010

Corindus announces clinical results of CorPath 200 System

Corindus Vascular Robotics announced the results of the first clinical study of the CorPath 200 System and invites attendees of the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference (September 21-25 in Washington, DC) to experience firsthand the CorPath 200 System.

21 Sep 2010

Clemson biochemist receives grants to study DNA repair pathways

A Clemson biochemist has received grants totaling $787,000 to study how cells repair damaged DNA, which can cause cancer and genetic illnesses. The U.S. Department of Defense (DoD) and the National Institutes of Health (NIH) awarded Weiguo Cao three-year funding to investigate two DNA repair pathways.

21 Sep 2010

St. Jude Medical granted European CE Mark for Athena deep brain stimulation therapy management system

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its new Athena™ programmer, a deep brain stimulation (DBS) therapy management system. This next-generation platform offers clinicians a powerful yet easy-to-use interface that enables them to set or adjust therapeutic parameters to optimize patient results.

20 Sep 2010

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.

20 Sep 2010

Micromet initiates MT103 phase 2 trial in adult ALL patients

Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.

20 Sep 2010

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride alone.

20 Sep 2010

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Athersys, Inc. announced today the publication of a key study in the October issue of Experimental Neurology conducted by researchers at Athersys, the University of Texas Medical School, the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, and Texas A&M University.

20 Sep 2010

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Oxygen Biotherapeutics announces CRADA Agreement amendment

Oxygen Biotherapeutics, Inc. today announced it has amended an existing Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC) to include preclinical trials using swine models to assess the safety and efficacy of Oxygen Biotherapeutics' proprietary Oxycyte perfluorocarbon emulsion (PFCE) for spinal cord injury (SCI) due to decompression sickness (DCS), and for hemorrhagic shock.

20 Sep 2010

$ONS trial results show promise for treating medically refractory chronic migraines: ONSTIM study$

ONS trial results show promise for treating medically refractory chronic migraines: ONSTIM study

Medtronic, Inc. announced that data from a multicenter, prospective, randomized, blinded, feasibility trial published today show promise for occipital nerve stimulation for treating medically refractory chronic migraines and support the need for further controlled study of the treatment. The study, called Occipital Nerve Stimulation for the Treatment of Intractable Migraine, included severely debilitated patients who had regularly experienced 15 or more headache days per month that were not responsive to currently available medical therapies.

18 Sep 2010

Therapy News and Research

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

NIMU, NMRC sign CRADA agreement

Scientists identify new pathway to control immune balance

Talecris Biotherapeutics announces 2010 eALTA award recipients

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

FG-4592 oral anemia therapy receives CTA approval from SFDA

Corindus announces clinical results of CorPath 200 System

Clemson biochemist receives grants to study DNA repair pathways

St. Jude Medical granted European CE Mark for Athena deep brain stimulation therapy management system

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Micromet initiates MT103 phase 2 trial in adult ALL patients

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Oxygen Biotherapeutics announces CRADA Agreement amendment

ONS trial results show promise for treating medically refractory chronic migraines: ONSTIM study

Two-thirds of public hospitals are in rural areas

UCLA conference to provide information about latest developments to help enhance quality of life of seniors

Pazopanib drug reduces thyroid cancer progression: Study

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News